Home › Products › Oncology › Lenris 4mg Capsule
Lenris 4mg Capsule
Salt Composition: LENVATINIB
- Manufacturer: MYLAN PHARMACEUTICALS PVT LTD
- Pack Size: 10 CAPSULE(s) IN A STRIP
- Dosage Form: CAPSULE
- Strength: 4MG
- Prescription Required
- Storage: Lenris 4mg Capsule should be stored at room temperature, between 20°C to 25°C (68°F to 77°F). Protected from light. Keep it in its original packaging until it is ready to be used. Keep reach out of the reach of children and pets. Should be disposed of properly.
₹1316.00₹1828.13
Inclusive of all taxes
Product Introduction
Lenris 4mg Capsule contains the active ingredient Lenvatinib, a tyrosine kinase inhibitor. It is indicated for progressive or advanced thyroid cancer when radioactive iodine therapy has not been beneficial. It is also used to treat previously untreated hepatocellular carcinoma in patients who are not eligible for surgical treatment. Anaplastic thyroid carcinoma, an advanced form of thyroid cancer, typically occurs in patients aged over 60 years. Clinical features include thyroid gland enlargement and firmness, along with hoarseness of voice resulting from paralysis of the laryngeal nerve. Hepatocellular carcinoma develops secondary to existing liver disease such as cirrhosis or chronic hepatitis B infection. Patients with a history of allergic reaction to Lenris 4mg Capsule or any of its components should not use this medication. Patients must inform their dentist or oral surgeon of Lenris 4mg Capsule use, as it may impair wound healing and increase bleeding risk.
Uses
Lenris 4mg Capsule is indicated to treat the following conditions: Certain types of advanced thyroid cancer Advanced Liver cancer Certain types of kidney cancer Endometrial cancer
How it works
Lenris 4mg Capsule blocks the enzyme receptor tyrosine kinases (RTKs). RTKs develop new blood vessels that supply oxygen and nutrients to the cells and help them grow. This medicine inhibits the receptors that facilitate the growth of blood vessels in tumor cells. RTKs are present in high concentrations in cancer cells, and administration of this medicine slows down the rate of cancer cellsâ growth and multiplication.
How to Use
Lenris 4mg Capsule is an oral medication that is usually taken once a day, at approximately the same time each day, with or without food. It should be taken as prescribed by a doctor or other healthcare provider. These capsules should be swallowed whole with a glass of water. They should not be crushed, chewed, or opened, as this can affect the way the medication is absorbed and decrease its effectiveness. You should not take a double dose to make up for the second dose.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious: Feeling numb or weak on 1 side of the body Severe headache Fever Confusion Difficulty speaking Vision changes Dizziness Chest pain or pressure Pain in arms, jaw, neck, and back Breathing problems Severe stomach pain Blood clot formation Blood in stools or coughing blood Liver problems Pain or soreness in the mouth, teeth, or jaw Common: High or low BP Loss of appetite Nausea, vomiting, constipation, diarrhea, or indigestion Tiredness Hoarse voice Leg swelling Rashes Pain in joints or muscles Hair loss Sleeplessness Protein in urine, frequent urination Low potassium, magnesium, and calcium levels in the blood Dehydration Skin problems Gall bladder inflammation Increase in the values of cholesterol, thyroid-stimulating hormone, digestive enzymes Delayed wound healing
Expert Tips
Stay in close contact with your healthcare provider and report any side effects or concerns immediately. Avoid pregnancy and breastfeeding during treatment. Use effective contraception while taking Lenris 4mg Capsule and for at least two weeks after stopping it. Do not give these capsules to children. Avoid eating grapefruit, as it can affect how your body absorbs the medicine. Use sunscreen and wear protective clothing outdoors to reduce the risk of sunburn or skin damage. Avoid strenuous activities until you know how the medicine affects you, and maintain a healthy, balanced diet to support your overall well-being.
References
- Eisai Europe Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th April 2023], https://www.medicines.org.uk/emc/files/pil.68100.pdf
- Suyama and Iwase, Lenvatinib: A promising molecular targeted agent for multiple cancers, Cancer Control, 2018, 25, 1-5, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056795/pdf/10/1177 10732710818789361.pdf
- Q.M. Anstee, D.E.J. Jones, Liver and Biliary Tract Disease, Davidsonâs Principles and Practice of Medicine, 22nd Edition, 20110, 921-988.
- M.W.J. Strachan, J. Newell-Price, Endocrine disease, Davidsonâs Principles & Practice of Medicine, 22nd Edition, 20110, 733-796.
- Eisai Inc U.S Food and Safety Drug Administration (FDA) [Last revised Aug 2018], [Accessed on 20th April 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2069107s007lbl.pdf
Safety Advice
Pregnancy: unsafe Lenris 4mg Capsule is unsafe during pregnancy as it can cause fetal harm. It is recommended to avoid this medication during pregnancy.
Lungs: unsafe Lenris 4mg Capsule can cause side effects that affect the lungs, such as cough, shortness of breath, and difficulty breathing. If a person experiences any of these symptoms while taking it, they should notify their healthcare provider right away.
Breastfeeding: unsafe Breastfeeding is not recommended while taking Lenris 4mg Capsule, as it can potentially harm the nursing infant.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.